189 related articles for article (PubMed ID: 9164547)
21. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
Järbe TU; Lamb RJ; Liu Q; Makriyannis A
Eur J Pharmacol; 2003 Apr; 466(1-2):121-7. PubMed ID: 12679148
[TBL] [Abstract][Full Text] [Related]
22. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
Darmani NA
Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
[TBL] [Abstract][Full Text] [Related]
23. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats.
Mansbach RS; Rovetti CC; Winston EN; Lowe JA
Psychopharmacology (Berl); 1996 Apr; 124(4):315-22. PubMed ID: 8739546
[TBL] [Abstract][Full Text] [Related]
24. Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
McMahon LR; France CP
Exp Clin Psychopharmacol; 2003 Nov; 11(4):286-93. PubMed ID: 14599262
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
McMahon LR; Ginsburg BC; Lamb RJ
Psychopharmacology (Berl); 2008 Jul; 198(4):487-95. PubMed ID: 17673980
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
Booker L; Naidu PS; Razdan RK; Mahadevan A; Lichtman AH
Drug Alcohol Depend; 2009 Nov; 105(1-2):42-7. PubMed ID: 19679411
[TBL] [Abstract][Full Text] [Related]
27. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.
Welch SP; Thomas C; Patrick GS
J Pharmacol Exp Ther; 1995 Jan; 272(1):310-21. PubMed ID: 7815346
[TBL] [Abstract][Full Text] [Related]
28. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
Adams IB; Compton DR; Martin BR
J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
[TBL] [Abstract][Full Text] [Related]
29. Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol.
Wise LE; Thorpe AJ; Lichtman AH
Neuropsychopharmacology; 2009 Aug; 34(9):2072-80. PubMed ID: 19322169
[TBL] [Abstract][Full Text] [Related]
30. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA.
Tersigni TJ; Rosenberg HC
Brain Res; 1996 Sep; 733(2):184-92. PubMed ID: 8891301
[TBL] [Abstract][Full Text] [Related]
31. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
Rinaldi-Carmona M; Pialot F; Congy C; Redon E; Barth F; Bachy A; Brelière JC; Soubrié P; Le Fur G
Life Sci; 1996; 58(15):1239-47. PubMed ID: 8614277
[TBL] [Abstract][Full Text] [Related]
32. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat.
Hohmann AG; Tsou K; Walker JM
J Neurophysiol; 1999 Feb; 81(2):575-83. PubMed ID: 10036261
[TBL] [Abstract][Full Text] [Related]
34. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
Lichtman AH; Wiley JL; LaVecchia KL; Neviaser ST; Arthur DB; Wilson DM; Martin BR
Eur J Pharmacol; 1998 Sep; 357(2-3):139-48. PubMed ID: 9797029
[TBL] [Abstract][Full Text] [Related]
35. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia.
Richardson JD; Aanonsen L; Hargreaves KM
J Neurosci; 1998 Jan; 18(1):451-7. PubMed ID: 9412521
[TBL] [Abstract][Full Text] [Related]
36. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
Pan X; Ikeda SR; Lewis DL
Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
[TBL] [Abstract][Full Text] [Related]
37. Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.
Bagüés A; Martín MI; Sánchez-Robles EM
Eur J Pharmacol; 2014 Dec; 745():69-75. PubMed ID: 25446925
[TBL] [Abstract][Full Text] [Related]
38. SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys.
McMahon LR; Amin MR; France CP
Behav Pharmacol; 2005 Sep; 16(5-6):363-72. PubMed ID: 16148440
[TBL] [Abstract][Full Text] [Related]
39. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea.
Parker LA; Mechoulam R; Schlievert C; Abbott L; Fudge ML; Burton P
Psychopharmacology (Berl); 2003 Mar; 166(2):156-62. PubMed ID: 12528012
[TBL] [Abstract][Full Text] [Related]
40. Dopamine D(2) receptor antagonists prevent delta(9)-tetrahydrocannabinol-induced antinociception in rats.
Carta G; Gessa GL; Nava F
Eur J Pharmacol; 1999 Nov; 384(2-3):153-6. PubMed ID: 10611435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
